| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/23/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 13.5% stake in PMV Pharmaceuticals, Inc. |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 10.2% stake in PMV PHARMACEUTICALS, INC. |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/19/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 4.9% stake in PMV Pharmaceuticals, Inc. |
| 05/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 1.4% stake in EXIT FILING PMV PHARMACEUTICALS INC |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/01/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
8-K
| Quarterly results |
| 03/01/2023 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 02/14/2023 |
SC 13G/A
| Boxer Capital, LLC reports a 6.9% stake in PMV Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| CITADEL ADVISORS LLC reports a 3% stake in PMV Pharmaceuticals, Inc. |
| 02/10/2023 |
SC 13G/A
| INTERWEST PARTNERS X LP reports a 3.8% stake in PMV Pharmaceuticals, Inc. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 6% stake in PMV Pharmaceuticals Inc. |
| 01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.6% stake in PMV PHARMACEUTICALS, INC. |
| 01/25/2023 |
SC 13G/A
| JPMORGAN CHASE & CO reports a 8.7% stake in PMV PHARMACEUTICALS, INC. |
| 01/24/2023 |
SC 13G/A
| Cowen Financial Products LLC reports a 3.3% stake in PMV Pharmaceuticals, Inc. |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|